# Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population

- 3
- 4 Zhigang Yi<sup>1,2\*#</sup>, Yun Ling<sup>1#</sup>, Xiaonan Zhang<sup>1#</sup>, Jieliang Chen<sup>2#</sup>, Kongying Hu<sup>2</sup>, Yuyan Wang<sup>2</sup>,
- 5 Wuhui song <sup>2</sup>, Tianlei Ying <sup>2</sup>, Rong Zhang <sup>2</sup>, Hongzou Lu <sup>1\*</sup>, Zhenghong Yuan <sup>2\*</sup>
- 6
- 7 1. Shanghai public health clinical center, Fudan University, Shanghai, 201508, PR China
- 8 2. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical
- 9 Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, PR China
- 10
- 11 # Co-first authors
- 12 \* Contact authors
- 13
- 14 Email: zgyi@fudan.edu.cn (Z. Yi); luhongzhou@shphc.org.cn (H, Lu); zhyuan@shmu.edu.cn (Z.
- 15 Yuan)
- 16
- 17
- 18

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 19 Abstract

20 Pandemic SARS-CoV-2 has infected over 10 million people and caused over 500,000 mortalities. Vaccine development is in urgent need to stop the pandemic. Despite great progresses 21 22 on SARS-CoV-2 vaccine development, the efficacy of the vaccines remains to be determined. 23 Deciphering the interactions of the viral epitopes with their elicited neutralizing antibodies in the 24 convalescent COVID-19 population inspires the vaccine development. In this study, we devised a 25 peptide array composed of 20-mer overlapped peptides of spike (S), membrane (M) and envelope 26 (E) proteins, and performed a screening with 120 COVID-19 convalescent serums and 24 27 non-COVID-19 serums. We identified five SARS-CoV-2-specific dominant epitopes that reacted 28 with above 40% COVID-19 convalescent serums. Epitopes in the receptor-binding domain (RBD) 29 of S ill reacted with the convalescent serums. Of note, two peptides non-specifically interacted with 30 most of the non-COVID-19 serums. Neutralization assay indicated that only five serums completely blocked viral infection at the dilution of 1:200. By using a peptide-compete neutralizing assay, we 31 32 found that three dominant epitopes partially competed the neutralization activity of several 33 convalescent serums, suggesting antibodies elicited by these epitopes played an important role in 34 neutralizing viral infection. The epitopes we identified in this study may serve as vaccine candidates to elicit neutralizing antibodies in most vaccinated people or specific antigens for SARS-CoV-2 35 36 diagnosis.

37

38 Key words: SARS-CoV-2; COVID-19; epitope; neutralizing antibody; vaccine; diagnosis

- 39
- 40
- 41

42

43

44

45

#### 47 Introduction

Since the outbreak of COVID-19 in Wuhan China in December 2019, it was endemic to all 48 over the China within less than one month and now become pandemic in over 200 countries. The 49 50 infected cases surged to over 10 million by the end of June 2020, with over 500,000 mortalities 51 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). COVID-19 is caused by 52 infection with a novel coronavirus SARS-CoV-2 (1-3). Efficacy of several antiviral agents such as 53 remdesivir and chloroquine remains uncertainty (4-6). Vaccine development is in urgent need to 54 stop the pandemic. Coronaviruses contains three structural proteins on the surface of virus 55 membrane envelope: the spike (S), membrane (M) and envelop (E) proteins. S protrudes from the 56 virion surface to form a spike and interacts with host receptor to mediate virus entry (7). The spike 57 protein (S) of SARS-CoV-2 interacts with host receptor ACE2 (2). SARS-CoV-2 vaccine 58 candidates include viral vector expressing SARS-CoV-2 spike protein (S) (8), the receptor binding 59 domain (RBD) (9) and inactivated virion (10). With the start of the first clinical trial of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine (8), there would be many other 60 61 vaccine trials. Despite great progresses on SARS-CoV-2 vaccine development, there are still critical 62 questions remains to be answered, such as which kind of antigens (epitopes) elicit robust neutralizing antibodies in most people; if the convalescent serum of COVID-19 patients contains 63 64 neutralizing antibodies and which viral epitopes are recognized by the neutralizing antibodies. 65 Answers to these questions may guide development of effective vaccines. In this study, we 66 collected the serums of a convalescent COVID-19 cohort. By using a peptide array composed of 67 20-mer overlapped peptides of S, M and E, we identified several dominant SARS-CoV-2 specific linear epitopes that reacted with the convalescent serums. By using peptide-compete neutralizing 68 69 assay, we found that some of these dominant epitopes partially competed the neutralization activity 70 of several convalescent serums. These data provide information for developing novel vaccine 71 candidates and antigens for specific antibody diagnosis.

72

#### 73 **Results**

#### 74 Identification of dominant linear B-cell epitopes of COVID-19 by a peptide array.

To map the dominant linear B-cell epitopes recognized by most COVID-19 patients, we designed a 20-mer overlapped peptide array encompassing the entire spike (S), the ectodomain of membrane (M), the loops between the transmembrane helices (TMs) and representative regions of endomains of M and envelope (E) proteins (Fig.1a and b)(Supplementary table 1). We used the peptide array to perform a screening with convalescent serums from 120 COVID-19 patients and 24 80 serums collected from patients with symptoms of acute respiratory infections but with negative diagnosis of COVID-19. The serums were diluted 1:200 and incubated with the peptide array, 81 82 followed by incubated with HRP-conjugated anti-human IgG. Peptides reacting with the serums 83 were visualized by chemiluminescent reagents. Of the 120 COVID-19 convalescent serums, 2 84 serums didn't react with any peptide; 4 serums only reacted with one peptide in the peptide array. 85 Peptides S1-52, S1-55, S1-57, S2-13, S2-47, M1 reacted with more than 40% COVID-19 serums (Fig. 1c and 1d). Of note, S1-52 and S2-56 reacted with more than 40% COVID-19-negative 86 87 control serums, indicating non-specific reaction (Fig. 1c and 1d). We also detected about 17% 88 serum reacted with a peptide (E2) in the endodomain of E whereas no reaction with the peptide in 89 the ectodomain (E1) (Fig. 1c and 1d). The topology of E protein remains controversial. Evidences 90 indicate the N-terminal part is the ectodomain (Fig. 1a)(11, 12). If the interaction of E endodomain 91 with antibodies is due to the real topologically exposure remains to be clarified.

The peptides S1-52, S1-55, S1-57, S2-13, S2-47, M1 that reacted with more than 40% COVID-19 serums represented as dominant linear B-cell epitopes. We located these epitopes in a crystal structure of S in open sate (PBD, 6vyb) (Fig. 2a and 2b). The peptides S1-52 and S1-55 were near the receptor-binding domain (RBD) (Fig. 2a and 2b). The peptide S2-13 contained the alternative S2' cleavages sites and fusion peptide (FP) (Fig. 2a and 2b). Most of the peptide S2-47 is not available in the crystal structure (Fig. 2a and 2b). Peptide S2-47 is conserved in SARS-CoV-2 and SARS-CoV whereas other peptide varied in SARS-CoV-2 and SARS-CoV (Fig. 2c).

#### 99 Less B-cell linear epitopes on Receptor binding domain (RBD) of Spike protein (S).

100 Receptor binding domain (RBD) of coronaviruses spike proteins interacts with host receptor to 101 mediate virus entry and some antibodies against RBD potently neutralize viral infection (7). We 102 examined the reactions of the RBD peptides with the serums (Fig. 3a). Except for S1-52, almost all 103 the RBD peptides reacted with less than 10% serums, with peptides such as S1-31, S1-32, S1-34 104 and S1-35 that didn't react with any serum (Fig. 3b). Although the peptide S1-52 interacted with 105 most serums, it also non-specifically interacted with control serums (Fig. 3c). A poor-interaction 106 peptide S1-31 was partially masked by the high-reaction peptide S1-52 in the crystal structures (Fig. 107 3c), suggesting the poor reaction of this peptide was probably due to its poor accessibility. In 108 contrast, the peptide S1-32 and the ACE-2 interacting-interface (Fig. 3a, in red) have good 109 accessibility (Fig. 3c) but still exhibited poor reactions (Fig. 3b), suggesting poor reactions of 110 peptides in RBD in general.

#### 111 Neutralizing SARS-CoV-2 infection by COVID-19 convalescent serum.

112

To explore the functional relevance of the identified B-cell linear epitopes and their elicited

113 antibodies with the neutralizing activity, we first assessed the activities of the serums for the 114 neutralization of SARS-CoV-2 virus infection. COVID-19 convalescent serums were diluted at 115 1:200 and incubated with 100 PFU (plague-forming unit) of virus. The neutralizing activity was 116 assessed by reduction of viral infection-induced cytopathic effect (CPE) and quantification of viral 117 RNA levels in the supernatants of the infected cells (Fig. 4a). We used a SARS-CoV-2 strain nCoV-SH01 that we isolated from the throat swab sample of a COVID-19 patient (13). Virus 118 119 infection induces typical syncytial cytopathic effects on Vero E6 cells (supplementary Fig. 1). Some 120 COVID-19 convalescent serums could partially reduce (CPE+, CPE++) the CPE or completely 121 blocked the appearance of CPE (CPE-) (supplementary Fig. 1; Supplementary table 2). Of the 120 122 COVID-19 convalescent serums tested, at the dilution of 1:200, five serums completely blocked the 123 appearance of CPE at 3 days post infection. And seven serums partially reduced the CPE or 124 completely blocked the appearance of CPE in one of the duplicated wells (Supplementary table 2). 125 We also quantified the viral RNA levels in the supernatants of the infected cells at 3 days post 126 infection with some representative samples. Serums P13, P18, P68, P98 and P107 that completely 127 blocked the appearance of CPE also dramatically reduced the viral RNA levels (Fig. 4b).

# 128 Competing the neutralizing activity of convalescent serum with dominant B-cell linear 129 epitopes.

130 Then we compared the peptide array reaction patterns of the neutralizing serums (Nab) with 131 the patterns of several non-neutralizing serums (Non-Nab). All the Nabs reacted with the dominant 132 epitopes S1-55, S1-57 and S2-13. In contrast, only part of the Non-nabs reacted with these epitopes 133 (Fig. 5a). Next, we evaluated if the antibodies against these epitopes play a role in activity of 134 neutralizing viral infection. We performed a neutralizing experiment by using the peptide S1-55, S1-57, S2-13 and S2-47 compete the neutralizing activity of four neutralizing serums (Fig. 5b). The 135 136 peptides were added at a final concentration of to 0.25mg/ml, at which, typically the peptide could completely block the corresponding antibodies (14). Adding of the peptides alone didn't affect viral 137 138 infection. Out of the four serums tested, peptides S1-55, S1-57 and S2-47 partially competed the 139 neutralizing activity of one or two of the serums (Fig. 5c), suggesting that antibodies against these 140 peptides partially contribute to the neutralizing activity of the serums.

# 141 Relationship of the neutralizing activity of the serums with the progress of the COVID-19142 disease

To explore if the relationship of the neutralizing activity of the serums with the progress of the
COVID-19 disease, we retrospectively analyzed the disease severity of the 120 COVID-19 patients.
Eight patients experienced severe symptoms and patients who have serums with complete or partial

neutralizing activity experienced asymptomatic or mild diseases (data not shown). We then examined the time intervals from the symptom onset to convalescence with SARS-CoV-2 triple negative diagnosis for throat swab, urine and feces. The average time interval for convalescence is 16.3 days. Patients with complete or neutralizing-antibodies (Fig. 6, in red and arrows) had variable time interval for convalescence, ranging from 8 days to 35 days, which was similar with the patients without neutralizing-antibodies (Fig. 6).

#### 152 **Discussion**

153 To learn the profile of the B-cell linear epitopes recognized by COVID-19 cohort for guiding 154 vaccine design and devising diagnosis reagents, we performed functional B-cell linear epitope 155 mapping with the convalescent serums of a COVID-19 cohort. By using a 20-mer-peptide array covering the S, M and E, we identified SARS-CoV-2 dominant epitopes recognized by most 156 157 COVID-19 convalescent serums (Fig. 1 and 2). By using peptide-compete neutralizing assay, we 158 found that epitopes in the peptides S1-55, S1-57 and S2-47 partially competed the neutralization 159 activity of several convalescent serums (Fig. 5), suggesting antibodies against these epitopes play 160 an important role in neutralizing viral infection. As the convalescent serum is composed of different 161 antibodies, it is expected that fully neutralization should be accomplished by the action of 162 antibodies against these identified epitopes and probably other spatial epitopes. When we were 163 preparing this manuscript, a similar study that used an 18-mer-peptide pool of spike proteins to 164 screen 25 COVID-19 convalescent serums by ELISA. They identified two dominant epitopes that 165 partially overlapped with the peptide S1-55 and S2-13 identified in this study (15). And depletion of 166 the COVID-19 convalescent serums by these two epitopes partially impaired the neutralizing 167 activity of the convalescent serums (15). In these study, in addition to these two peptides, we identified three other dominant epitopes: the epitopes in peptide S1-57 that is close to the peptide 168 169 S1-55, the peptide S2-47 that is near the membrane proximal region of S and the ectodomain of M (Fig. 1 and 2). Notably, peptide S1-57 competed the neutralizing activity of two serums out of four 170 171 serums tested (Fig. 5), suggesting the antibodies against this peptide play an import role in 172 neutralizing activity. In contrast, peptide S2-13 didn't compete the neutralizing activity of the 173 serums tested, which is inconsistent to the previous study (15). The discrepancy might be due to the 174 variation of the serums used.

We noticed two peptides S1-52 that is in the receptor-binding domain and S2-56 that is in the endomain of S highly reacted with SARS-CoV-2 negative serums (Fig. 1), pointing to a risk for using the whole S or RBD as a reagent for diagnosis of SARS-CoV-2 antibodies. The dominant

peptides S1-57 and M1 specifically reacted with COVID-19 serums and may provide goodcandidates for diagnosis reagents.

RBD of coronaviruses spike proteins mediate virus entry and antibodies against RBD potently 180 181 neutralize viral infection. To our surprise, we detected much less interactions of the peptides in 182 RBD with the serums, except for the peptide S1-52 (Fig. 3). Of the 120 serums, only 5 serums 183 completely neutralized and 7 serums partially neutralized viral infection at the dilution of 1:200. 184 The relative low percentage of neutralizing antibody might be due to the poor recognition of RBD 185 linear epitopes. Alternatively the most of the RBD epitopes are conformational epitopes. We can 186 not rule out the possibility that the non-neutralizing antibodies could sterilize viral infection by 187 other mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) (16).

In summary, we identified the dominant B-cell linear epitopes of SARS-CoV-2 in a COVID-19 cohort. Antibodies elicited by some of these antibodies played an important role in neutralizing viral infection. These epitopes may serve as a vaccine candidate to elicit neutralizing antibodies in most vaccinated people or a specific antigen for SARS-CoV-2 diagnosis.

#### 192 Methods

#### 193 Ethics statements

This study was approved by the ethics committee of Shanghai public health clinical center, and the procedures were carried out in accordance with approved guidelines. Informed consent was obtained from the subjects. Collection of the COVID-19 convalescent serum samples was approved under the study number YJ-2020-S077-02. The serum samples of patients with symptoms of acute respiratory infections were collected under the study number YJ-2018-S045-02.

#### **Peptide array**

According to a sequence of SARS-CoV-2 (Accession number, MT121215), 20-mer overlapped peptides covering the entire spike (S) region, the ectodomain of membrane (M), the loops between the TMs and representative regions of endomains of M and envelope (E) were synthesized by GL Biochem (Shanghai, China) and purified by HPLC. Peptides were printed onto activated integrated poly (dimethysiloxane) membrane (iPDMS) as described (14).

#### 205 Serum screening

Serums were diluted (1:200) and incubated with peptide array. After wash, the peptide arrays were incubated with Horseradish peroxidase (HRP)-conjugated goat anti-human IgG. Dots were visualized by Super Signal Femto Maximum Sensitivity Substrate for Chemiluminescence (Thermo Fischer) and pictures were captured by a cool CCD. The chemiluminescence intensity of each dot

- 210 was converted to signal-to-noise ratio (SNR) by subtracting the background intensity averaged from
- the intensity from blank dots. SNR equal or above 2 is considered as positive.
- 212 Cells
- 213 Vero E6 cells were maintained in Dulbecco's modified eagle medium (DMEM)( Hyclone)
- containing 10% FBS (BI) supplemented with 1% penicillin, and streptomycin (Hyclone).
- 215 Virus and neutralization assay
- 216 SARV-CoV-2 virus experiment was carried out in the biosafety level 3 (BSL-3) laboratory in the 217 Shanghai medical college, Fudan University. SARV-CoV-2 virus strain nCoV-SH01 was isolated from a throat swab sample on Vero E6 cells (13), propagated and titrated on Vero E6 cells by a 218 plague assay. For neutralization assay,  $5 \times 10^4$  Vero E6 cells were seeded onto 96 well plates. 219 220 Serums were diluted 1:100 in DMEM supplemented with 2% FBS, incubated with 100 PFU of 221 SARV-CoV-2 virus at 37°C for 1 hours, and then the mixture was added to equal volume of cell medium (the final dilution of serum is 1:200). After infection for 2 hours, cells were washed once 222 223 with DPBS and added with fresh media. For peptide competing experiment, serums were diluted 224 1:100 in DMEM supplemented with 2% FBS, incubated with 100 PFU of SARV-CoV-2 virus and 225 indicated peptides at a conerntration of 0.5mg/ml at 37°C for 1 hours, and then the mixture was 226 added to equal volume of cell medium (the final dilution of serum is 1:200 and the final 227 concentration of peptide is 0.25mg/ml).

#### 228 Quantitative real-time PCR

Supernatants from infected cells were mixed with Trizol LS (Invitrogen). RNAs were extracted by phenol/chloroform and precipitated by isopropanol. After wash with 70% ethanol, RNAs were dissolved in nuclease-free water and quantified by a Taqman-based real time PCR with One Step PrimeScript RT-PCR kit (Takara) according to the manufacturers' protocol with 400nM of each primer (sense primer: GAA AAT AGG ACC TGA GCG CAC C, anti-sense primer: TGA CAA TAC AGA TCA TGG TTG CTT TGT) and 200nM of probe (FAM- TAG ACG TGC CAC ATG CTT TTC CAC TGC TTC AGA C -BHQ1). The relative RNA levels were calculated by  $2^{-\Delta CT}$ 

236 method (17).

# 237 COVID-19 screening

238 We selected throat swab samples of patients with symptoms of acute respiratory infections that

- 239 were collected before the COVID-19 outbreak and extracted the nucleic acid. COVID-19 diagnosis
- 240 was performed by Quantitative real-time PCR as described above.

#### 241 Data processing

242 MegAlign (DNAstar) was used for protein sequence alignment analysis. Transmembrane helices

- 243 prediction was done by TMHMM program (http://www.cbs.dtu.dk/services/TMHMM-2.0/).
- 244 Structure data of open state of S was retrieved (PDB, 6vyb) and visualized by UCSF Chimera.

# 245 Funding

246 This work was supported in part by the National Science and Technology Major Project of

- 247 China (2017ZX10103009). Key Emergency Project of Shanghai Science and Technology
- 248 Committee (20411950103). The funders had no role in study design, data collection and analysis,
- 249 decision to publish, or preparation of the manuscript.

#### 250 Disclosure statement

251 The authors declare no conflict of interest.

#### 252 Author Contributions

- 253 Conceived the study: J Chen, T Ying, Z Yi; conducted the study: K Hu, Y Wang, W Song, R Zhang,
- 254 Z Yi; clinical sample: Y Ling, X Zhang, H Lu; Data analysis: Z Yi, X Zhang, K Hu, Y Wang;
- 255 Manuscript draft: Z Yi; Resources: Z Yuan, H LU, Z Yi.
- 256
- 257

#### 258 **References:**

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,
   Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I,
   Research T. 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019.
   The New England journal of medicine 382:727-733.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL,
   Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng
   XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. 2020.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin.
   Nature.
- Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, Sun Z, Liu F, Wu K, Zhong B, Mei Y,
  Zhang W, Chen Y, Li Y, Shi M, Lan K, Liu Y. 2020. RNA based mNGS approach
  identifies a novel human coronavirus from two individual pneumonia cases in 2019
  Wuhan outbreak. Emerging microbes & infections 9:313-319.
- Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G,
   Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X,
   Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L,
   Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B,
   Wang C. 2020. Remdesivir in adults with severe COVID-19: a randomised,
   double-blind, placebo-controlled, multicentre trial. Lancet 395:1569-1578.
- 5. Bonovas S, Piovani D. 2020. Compassionate Use of Remdesivir in Covid-19. The New
  England journal of medicine 382:e101.
- Wong YK, Yang J, He Y. 2020. Caution and clarity required in the use of chloroquine
  for COVID-19. The Lancet Rheumatology 2:e255.
- 282 7. **Masters PS, Perlman S.** sixth edition. Coronaviridae. Fields Virology:825-858.

Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L,
 Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W,
 Chen W. 2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus
 type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised,
 first-in-human trial. Lancet 395:1845-1854.

Brain D, Mou H, Zhang L, Guo Y, He W, Oiha A, Mark S, Luo G, Li W, Zhong G, Choe
 H, Farzan M. 2020. The SARS-CoV-2 receptor-binding domain elicits a potent
 neutralizing response without antibody-dependent enhancement. bioRxiv

#### **2020.04.10.036418**.

- Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X,
  Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D,
  Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. 2020. Rapid
  development of an inactivated vaccine candidate for SARS-CoV-2. Science.
- 296 11. Corse E, Machamer CE. 2002. The cytoplasmic tail of infectious bronchitis virus E
   297 protein directs Golgi targeting. Journal of virology 76:1273-1284.
- Vennema H, Godeke GJ, Rossen JW, Voorhout WF, Horzinek MC, Opstelten DJ,
   Rottier PJ. 1996. Nucleocapsid-independent assembly of coronavirus-like particles by
   co-expression of viral envelope protein genes. The EMBO journal 15:2020-2028.
- 301 13. Zhang R, Yi Z, Wang Y, Teng Z, Xu W, Song W, Cai X, Sun Z, Gu C, Zhou Y, Chen H, Ye
  302 Y, Han W, Zhu Y, Feng X, Fang F, Li C, Zhang X, Qu D, Fu C, Xie H, Yuan Z. 2020.
  303 Isolation of a 2019 novel coronavirus strain from a coronavirus disease 19 patient in
  304 Shanghai. Journal of Microbes and Infection 15:15-20.
- 305 14. Zhang H, Song Z, Yu H, Zhang X, Xu S, Li Z, Li J, Xu H, Yuan Z, Ma H, Yi Z, Hu Y. 2018.
   306 Genome-wide linear B-cell epitopes of enterovirus 71 in a hand, foot and mouth
   307 disease (HFMD) population. Journal of clinical virology : the official publication of the
   308 Pan American Society for Clinical Virology 105:41-48.
- 309 15. Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY, Chee RS, Fong SW, Yeo NK, Lee
  310 WH, Torres-Ruesta A, Leo YS, Chen MI, Tan SY, Chai LYA, Kalimuddin S, Kheng
  311 SSG, Thien SY, Young BE, Lye DC, Hanson BJ, Wang CI, Renia L, Ng LFP. 2020. Two
  312 linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in
  313 COVID-19 patients. Nature communications 11:2806.
- 314 16. Forthal DN, Finzi A. 2018. Antibody-dependent cellular cytotoxicity in HIV infection.
  315 Aids 32:2439-2451.
- Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using
   real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
- 318
- 319

#### 320 Figure Legends

Figure 1. Screening convalescent serum of COVID-19 by peptide array. (a) Schematic 321 of SARS-CoV-2 virion structural proteins: spike (S), membrane (M) and envelope (E) proteins. In 322 323 the diagram of S, the receptor-binding domain (RBD) is in red. Fusion peptide (FP) is in green. Black boxes indicate transmembrane helices (TM). Arrows indicate S1/S2 cleavage site and 324 325 alternative S2' cleavages sites, respectively. In the diagrams of M and E, the endodomians and 326 ectodomains are indicated. The numbers above the diagrams indicate the positions (aa) of each 327 domain. (b) Design of peptide array. 20-mer overlapped peptides covering the entire S, the 328 ectodomain of M, the loops between the TMs and representative regions of endomains of M and E 329 were synthesized and doted. (c-d) Convalescent serums from COVID-19 patients and control 330 serums from non-COVID-19 patients (control serum) were diluted (1:200) and incubated with 331 peptide array, followed by incubated with HRP-conjugated anti-human IgG. Peptide array were 332 visualized by chemiluminescent reagents, scanned and quantified. The peptides with signal to noise 333 above 2 were counted as positive (black bar). The positive peptides for each patient were plotted. 334 Arrows indicate representative peptides. (d) The positive percentage of the indicated peptides.

Figure 2. Identification of dominant B-cell linear epitopes of SARS-CoV-2 virus particle. (a) Schematic of spike (S), membrane (M) and the dominant B-cell linear epitopes (red lines). (b) Locations of the dominant B-cell linear epitopes in the S structure. The S structure (open sate; PBD, 6vyb), N-terminal domain (cyan), RBD (red), fusion peptide (green). The B-cell linear epitopes are in black. Only part of the S2-47 is visible in the structure. (c) Alignment of the dominant B-cell linear epitopes. Different amino acids are in red. Fusion peptide in S2-13 is in green.

Figure 3. Less B-cell linear epitopes on Receptor binding domain (RBD) of Spike protein
(S). (a) Amino acid sequence of RBD. Black bars indicate the corresponding peptides. The ACE-2
interacting interface was in red. (b) Reaction of COVID-19 convalescent serums with the peptides
in RBD. The peptides with signal to noise above 2 were counted as positive (black bar). (c)
Representative peptide (in black) in the structure of RBD (PBD, 6vyb).

Figure 4. Neutralizing SARS-CoV-2 infection by COVID-19 convalescent serum. (a) Schematic of experiment design. COVID-19 convalescent serums were diluted and incubated with SARS-CoV-2 before added to the media. At 48 hours or 72 hours post infection (p.i), the cytopathic effect (CPE) of the infected cells was examined. The viral RNAs in the supernatants were quantified by real-time PCR (q-PCR). (b) Quantification of the viral RNA levels in the supernatants from representative wells. Relative RNA levels to the mock-treated wells were plotted (n=2).

352 Figure 5. Competing the neutralizing activity of convalescent serum with dominant

353 B-cell linear epitopes. (a) Reaction of the neutralizing antibodies (Nab) and non-neutralizing 354 antibodies (Non-Nab) with the peptide array. The peptides with signal to noise above 2.1 were 355 counted as positive (black bar). (b) Schematic of experiment design. Four neutralizing serums (P13, 356 P18, P68 and P98) were diluted and incubated with SARS-CoV-2 and the peptides (S1-55, S1-57, S2-13 and S2-47), respectively before added to the media. At 24 p.i, the viral RNAs in the 357 358 supernatants were quantified by q-PCR. Experiment was done in duplicated well for each serum (b) 359 Quantification of the viral RNA levels in the supernatants from representative wells. Relative RNA 360 levels to the mock-treated wells were plotted (n=2).

Figure 6. Time intervals from symptom onset to SARS-CoV-2 triple negative diagnosis. Time intervals from symptom onset to SARS-CoV-2 triple negative diagnosis for throat swab, urine and feces. Serums with neutralizing activity are in red. Arrows indicate fully neutralizing antibodies.

- 365
- 366
- 367
- 368
- 369





372 Figure 1. Screening convalescent serum of COVID-19 by peptide array. (a) Schematic of 373 SARS-CoV-2 virion structural proteins: spike (S), membrane (M) and envelope (E) proteins. In the 374 diagram of S, the receptor-binding domain (RBD) is in *red*. Fusion peptide (FP) is in *green*. Black 375 boxes indicate transmembrane helices (TM). Arrows indicate S1/S2 cleavage site and alternative S2' 376 cleavages sites, respectively. In the diagrams of M and E, the endodomians and ectodomains are 377 indicated. The numbers above the diagrams indicate the positions (aa) of each domain. (b) Design 378 of peptide array. 20-mer overlapped peptides covering the entire S, the ectodomain of M, the loops 379 between the TMs and representative regions of endomains of M and E were synthesized and doted. 380 (c-d) Convalescent serums from COVID-19 patients and control serums from non-COVID-19 patients (control serum) were diluted (1:200) and incubated with peptide array, followed by 381 382 HRP-conjugated anti-human IgG. Peptide array were visualized by incubated with 383 chemiluminescent reagents, scanned and quantified. The peptides with signal to noise above 2 were counted as positive (black bar). The positive peptides for each patient were plotted. Arrows indicate 384 385 representative peptides. (d) The positive percentage of the indicated peptides.

- 386
- 387



Schematic of spike (S), membrane (M) and the dominant B-cell linear epitopes (red lines). (b) Locations of the dominant B-cell linear epitopes in the S structure. The S structure (open sate; PBD, 6vyb), N-terminal domain (cyan), RBD (red), fusion peptide (green). The B-cell linear epitopes are in black. Only part of the S2-47 is visible in the structure. (c) Alignment of the dominant B-cell linear epitopes. Different amino acids are in red. Fusion peptide in S2-13 is in green.

# **Figure 3**



Figure 3. Less B-cell linear epitopes on Receptor binding domain (RBD) of Spike protein (S).
(a) Amino acid sequence of RBD. Black bars indicate the corresponding peptides. The ACE-2
interacting interface was in red. (b) Reaction of COVID-19 convalescent serums with the peptides
in RBD. The peptides with signal to noise above 2 were counted as positive (black bar). (c)
Representative peptide (in black) in the structure of RBD (PBD, 6vyb).





**Figure 4. Neutralizing SARS-CoV-2 infection by COVID-19 convalescent serum.** (a) Schematic of experiment design. COVID-19 convalescent serums were diluted and incubated with SARS-CoV-2 before added to the media. At 48 hours or 72 hours post infection (p.i), the cytopathic effect (CPE) of the infected cells was examined. The viral RNAs in the supernatants were quantified by real-time PCR (q-PCR). (b) Quantification of the viral RNA levels in the supernatants from representative wells. Relative RNA levels to the mock-treated wells were plotted (n=2).

# 418 Figure 5



Figure 5. Competing the neutralizing activity of convalescent serum with dominant B-cell 420 421 linear epitopes. (a) Reaction of the neutralizing antibodies (Nab) and non-neutralizing antibodies (Non-Nab) with the peptide array. The peptides with signal to noise above 2.1 were counted as 422 423 positive (black bar). (b) Schematic of experiment design. Four neutralizing serums (P13, P18, P68 424 and P98) were diluted and incubated with SARS-CoV-2 and the peptides (S1-55, S1-57, S2-13 and 425 S2-47), respectively before added to the media. At 24 p.i, the viral RNAs in the supernatants were 426 quantified by g-PCR. Experiment was done in duplicated well for each serum (b) Quantification of the viral RNA levels in the supernatants from representative wells. Relative RNA levels to the 427 428 mock-treated wells were plotted (n=2).

429

419



Figure 6. Time interval for convalescence. Time intervals from symptom onset to SARS-CoV-2 triple negative diagnosis for throat swab, urine and feces. Serums with neutralizing activity are in red. Arrows indicate fully neutralizing antibodies.